-
公开(公告)号：KR20180056778A
公开(公告)日：2018-05-29
申请号：KR20187012991
申请日：2016-10-06
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： YAMASHITA SACHIKO , HIKICHI TETSURO
CPC classification number: A61K35/12 , A61K35/17 , A61K38/00 , A61K48/00 , C07K7/06 , C12N5/10 , C12N15/09 , G01N33/15 , G01N33/50
Abstract: 본발명은세포독성 T 세포를유도할수 있는 FOXM1 유래에피톱펩티드를제공한다. 본발명은더 나아가, 상기펩티드를코딩하는폴리뉴클레오티드, 상기펩티드를제시하는항원제시세포, 및상기펩티드를타겟하는세포독성 T 세포뿐만아니라, 항원제시세포또는 CTL의유도방법도제공한다. 본발명은또한유효성분으로서그들을포함하는조성물또는약학적조성물을제공한다. 더나아가, 본발명은본 발명의펩티드, 폴리뉴클레오티드, 항원제시세포, 세포독성 T 세포또는약학적조성물을사용하여암의치료및/또는예방방법, 및/또는이의수술후 재발을예방하는방법을제공한다. 암에대해면역반응을유도하는방법도또한제공한다.
-
公开(公告)号：KR20180055892A
公开(公告)日：2018-05-25
申请号：KR20187012067
申请日：2016-10-06
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： YAMASHITA SACHIKO , HIKICHI TETSURO
CPC classification number: A61K35/15 , A61K35/17 , A61K39/00 , A61K48/00 , C07K7/06 , C07K16/28 , C12N1/00 , C12N15/09
Abstract: 본발명은세포독성 T 세포를유도할수 있는 MPHOSPH1-유래에피톱펩티드를제공한다. 본발명은더 나아가, 상기펩티드를코딩하는폴리뉴클레오티드, 상기펩티드를제시하는항원제시세포, 및상기펩티드를타겟하는세포독성 T 세포뿐만아니라, 항원제시세포또는 CTL의유도방법도제공한다. 본발명은또한유효성분으로서그들을포함하는조성물또는약학적조성물을제공한다. 더나아가, 본발명은본 발명의펩티드, 폴리뉴클레오티드, 항원제시세포, 세포독성 T 세포또는약학적조성물을사용하여암의치료및/또는예방방법, 및/또는이의수술후 재발을예방하는방법을제공한다. 암에대해면역반응을유도하는방법도또한제공한다.
-
公开(公告)号：AU2020202435B2
公开(公告)日：2022-05-26
申请号：AU2020202435
申请日：2020-04-08
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： TSUNODA TAKUYA , OSAWA RYUJI , YAMASHITA SACHIKO , WATANABE TOMOHISA , HIKICHI TETSURO
IPC: C07K7/06 , A61K35/12 , A61K35/14 , A61K39/00 , A61K48/00 , A61P35/00 , A61P37/04 , C07K7/08 , C07K16/18 , C12N5/10 , C12N15/09
Abstract: The present invention provides an epitope peptide that is derived from KOC 1 and that has cytotoxic T cell induction potency. The present invention also provides a 5 polynucleotide that codes for the peptide, antigen-presenting cells that present the peptide and cytotoxic T cells that target the peptide, and a method for inducing the antigen presenting cells or the cytotoxic T cells. The present invention also provides a composition and a pharmaceutical composition that include the peptide, etc. as active components. The present invention also 10 provides a method for the treatment and/or prevention of cancer and/or the prevention of the post 0 operative recurrence of cancer, the method using the peptide, the polynucleotide, the antigen-presenting cells, and the cytotoxic T cells of the present invention or using the pharmaceutical composition of the present invention. The present invention also provides f a method for inducing an immune response to cancer.
-
公开(公告)号：AU2022202751A1
公开(公告)日：2022-05-19
申请号：AU2022202751
申请日：2022-04-27
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： YAMASHITA SACHIKO , HIKICHI TETSURO
Abstract: The present invention provides DEPDC1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：AU2016306527B2
公开(公告)日：2022-03-17
申请号：AU2016306527
申请日：2016-08-10
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： YAMASHITA SACHIKO , HIKICHI TETSURO
Abstract: The present invention provides an epitope peptide derived from DEPDC1 having cytotoxic T cell inducing ability. The present invention also provides a polynucleotide encoding the peptide, an antigen-presenting cell presenting the peptide and a cytotoxic T cell targeting the peptide, and a method for inducing the antigen-presenting cells or the CTL. The present invention further provides pharmaceutical compositions and compositions containing the same as an active component. Furthermore, the present invention provides a method for treating and/or preventing cancer, and/or a method for preventing the post-operative recurrence of cancer, using this peptide, polynucleotide, antigen-presenting cell, or cytotoxic T cell, or using this pharmaceutical composition. Further provided is a method for inducing an immune response to cancer.
-
Patent Agency Ranking
公开(公告)号：AU2020202681A1
公开(公告)日：2020-05-14
申请号：AU2020202681
申请日：2020-04-22
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： TSUNODA TAKUYA , OSAWA RYUJI , YAMASHITA SACHIKO , WATANABE TOMOHISA
IPC: C07K7/06 , A61K35/12 , A61K35/14 , A61K38/00 , A61K39/395 , A61K48/00 , A61P1/04 , A61P1/16 , A61P11/00 , A61P13/08 , A61P13/10 , A61P13/12 , A61P15/00 , A61P19/00 , A61P25/00 , A61P35/00 , A61P35/02 , A61P37/04 , C07K7/08 , C07K16/28 , C12N5/078 , C12N5/0783 , C12N5/10 , C12N15/09
Abstract: The present invention provides CDCAl-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the 5 peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, 10 antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：AU2020202435A1
公开(公告)日：2020-05-07
申请号：AU2020202435
申请日：2020-04-08
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： TSUNODA TAKUYA , OSAWA RYUJI , YAMASHITA SACHIKO , WATANABE TOMOHISA , HIKICHI TETSURO
IPC: C07K7/06 , A61K35/12 , A61K35/14 , A61K39/00 , A61K48/00 , A61P35/00 , A61P37/04 , C07K7/08 , C07K16/18 , C12N5/10 , C12N15/09
Abstract: The present invention provides an epitope peptide that is derived from KOC 1 and that has cytotoxic T cell induction potency. The present invention also provides a 5 polynucleotide that codes for the peptide, antigen-presenting cells that present the peptide and cytotoxic T cells that target the peptide, and a method for inducing the antigen presenting cells or the cytotoxic T cells. The present invention also provides a composition and a pharmaceutical composition that include the peptide, etc. as active components. The present invention also 10 provides a method for the treatment and/or prevention of cancer and/or the prevention of the post 0 operative recurrence of cancer, the method using the peptide, the polynucleotide, the antigen-presenting cells, and the cytotoxic T cells of the present invention or using the pharmaceutical composition of the present invention. The present invention also provides f a method for inducing an immune response to cancer.
-
公开(公告)号：AU2015300260B2
公开(公告)日：2020-01-02
申请号：AU2015300260
申请日：2015-07-31
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： TSUNODA TAKUYA , OSAWA RYUJI , YAMASHITA SACHIKO , WATANABE TOMOHISA , HIKICHI TETSURO
IPC: C07K7/06 , A61K31/7088 , A61K38/00 , A61K39/00 , A61K48/00 , A61P35/00 , C07K7/08 , C07K16/18 , C12N5/0783 , C12N5/0784 , C12N5/0786 , C12N5/10 , C12N15/09 , C12Q1/02 , G01N33/15 , G01N33/50
Abstract: The present invention provides an epitope peptide derived from URLC10 and having a cytotoxic T-cell induction ability. The present invention also provides: a polynucleotide for coding the peptide; an antigen-presenting cell presenting the peptide, and a cytotoxic T-cell for targeting the peptide; and a method for inducing the antigen-presenting cell or the CTL. The present invention further provides a composition containing these as an active ingredient thereof, and a pharmaceutical composition. The present invention also provides a method for treating and/or preventing cancer, and/or preventing a relapse of cancer after surgery, by using the peptide, polynucleotide, antigen-presenting cell, cytotoxic T-cell, or pharmaceutical composition. Furthermore, the present invention provides a method for inducing an immune response against cancer.
-
公开(公告)号：SG11201700839SA
公开(公告)日：2017-03-30
申请号：SG11201700839S
申请日：2015-07-31
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： TSUNODA TAKUYA , OSAWA RYUJI , YAMASHITA SACHIKO , WATANABE TOMOHISA
IPC: C07K7/06 , A61K35/12 , A61K35/14 , A61K38/00 , A61K39/395 , A61K48/00 , A61P1/04 , A61P1/16 , A61P11/00 , A61P13/08 , A61P13/10 , A61P13/12 , A61P15/00 , A61P19/00 , A61P25/00 , A61P35/00 , A61P35/02 , A61P37/04 , C07K7/08 , C07K16/28 , C12N5/078 , C12N5/0783 , C12N5/10 , C12N15/09
Abstract: The present invention provides CDCA1-derived epitope peptides having the ability to induce cytotoxic T cells. The present invention further provides polynucleotides encoding the peptides, antigen-presenting cells presenting the peptides, and cytotoxic T cells targeting the peptides, as well as methods of inducing the antigen-presenting cells or CTLs. The present invention also provides compositions and pharmaceutical compositions containing them as an active ingredient. Further, the present invention provides methods of treating and/or preventing cancer, and/or preventing postoperative recurrence thereof, using the peptides, polynucleotides, antigen-presenting cells, cytotoxic T cells or pharmaceutical compositions of the present invention. Methods of inducing an immune response against cancer are also provided.
-
公开(公告)号：AU2015300256A2
公开(公告)日：2017-03-16
申请号：AU2015300256
申请日：2015-07-31
Applicant: ONCOTHERAPY SCIENCE INC
Inventor： TSUNODA TAKUYA , OSAWA RYUJI , YAMASHITA SACHIKO , WATANABE TOMOHISA , HIKICHI TETSURO
IPC: C07K7/06 , A61K35/12 , A61K35/14 , A61K39/00 , A61K48/00 , A61P35/00 , A61P37/04 , C07K7/08 , C07K16/18 , C12N5/10 , C12N15/09
Abstract: The present invention provides an epitope peptide that is derived from KOC1 and that has cytotoxic T cell induction potency. The present invention also provides a polynucleotide that codes for the peptide, antigen-presenting cells that present the peptide and cytotoxic T cells that target the peptide, and a method for inducing the antigen-presenting cells or the cytotoxic T cells. The present invention also provides a composition and a pharmaceutical composition that include the peptide, etc. as active components. The present invention also provides a method for the treatment and/or prevention of cancer and/or the prevention of the postoperative recurrence of cancer, the method using the peptide, the polynucleotide, the antigen-presenting cells, and the cytotoxic T cells of the present invention or using the pharmaceutical composition of the present invention. The present invention also provides a method for inducing an immune response to cancer.
-
-
-
-
-
-
-
-
-
Search Results
63
records
(took 0.031 seconds)
